Decisional Conflict Regarding Disease-Modifying Treatment Choices Among Patients with Mid-Stage Relapsing-Remitting Multiple Sclerosis
DOI: https://doi.org/10.2147/ppa.s459242
2024-06-08
Patient Preference and Adherence
Abstract:Julia Sabin, 1 Elisa Salas, 2 Jesús Martín-Martínez, 3 Antonio Candeliere-Merlicco, 4 Francisco Javier Barrero Hernández, 5 Ana María Alonso Torres, 6 José Luis Sánchez-Menoyo, 7 Laura Borrega, 8 María Rodríguez-Rodríguez, 9 Montserrat Gómez-Gutiérrez, 10 Sara Eichau, 11 Miguel Ángel Hernández-Pérez, 12 Carmen Calles, 13 Eva Fernandez-Diaz, 14 Olga Carmona, 15 Aida Orviz, 16 Ana López-Real, 17 Pablo López-Muñoz, 18 Amelia Mendoza Rodríguez, 19 Eduardo Aguera-Morales, 20 Jorge Maurino 2 1 Department of Neurology, Hospital Universitario Puerta de Hierro, Madrid, Spain; 2 Medical Department, Roche Farma, Madrid, Spain; 3 Department of Neurology, Hospital Universitario Miguel Servet, Zaragoza, Spain; 4 Department of Neurology, Hospital Rafael Méndez, Lorca, Spain; 5 Department of Neurology, Hospital Clínico Universitario San Cecilio, Granada, Spain; 6 Department of Neurology, Hospital Regional Universitario de Málaga, Málaga, Spain; 7 Department of Neurology, Hospital de Galdakao-Usansolo, Galdakao, Spain; 8 Department of Neurology, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain; 9 Department of Neurology, Hospital Universitario Lucus Augusti, Lugo, Spain; 10 Department of Neurology, Hospital San Pedro de Alcántara, Cáceres, Spain; 11 Department of Neurology, Hospital Universitario Virgen Macarena, Sevilla, Spain; 12 Department of Neurology, Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain; 13 Department of Neurology, Hospital Universitario Son Espases, Palma de Mallorca, Spain; 14 Department of Neurology, Hospital Universitario de Albacete, Albacete, Spain; 15 Department of Neurology, Fundació Salut Empordà, Figueres, Spain; 16 Department of Neurology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; 17 Department of Neurology, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; 18 Department of Neurology, Hospital Arnau de Vilanova, Llíria, Spain; 19 Department of Neurology, Complejo Asistencial de Segovia, Segovia, Spain; 20 Department of Neurology, Hospital Universitario Reina Sofía, Córdoba, Spain Correspondence: Jorge Maurino, Ribera del Loira 50, Madrid, 28042, Spain, Tel + 34 913 24 81 00, Email Purpose: Shared decision-making is critical in multiple sclerosis (MS) due to the uncertainty of the disease trajectory over time and the large number of treatment options with differing efficacy, safety and administration characteristics. The aim of this study was to assess patients' decisional conflict regarding the choice of a disease-modifying therapy and its associated factors in patients with mid-stage relapsing-remitting multiple sclerosis (RRMS). Methods: A multicenter, non-interventional study was conducted. Adult patients with a diagnosis of RRMS (2017 revised McDonald criteria) and disease duration of 3 to 8 years were included. The level of uncertainty experienced by a patient when faced with making a treatment choice was assessed using the 4-item Decisional Conflict Scale. A battery of patient-reported and clinician-rated measures was administered to obtain information on symptom severity, illness perception, illness-related uncertainty, regret, MS knowledge, risk taking behavior, preferred role in the decision-making process, cognition, and self-management. Patients were recruited during routine follow-up visits and completed all questionnaires online using electronic tablets at the hospital. A multivariate logistic regression analysis was conducted. Results: A total of 201 patients were studied. Mean age (Standard deviation) was 38.7 (8.4) years and 74.1% were female. Median disease duration (Interquartile range) was 6.0 (4.0– 7.0) years. Median EDSS score was 1.0 (0– 2.0). Sixty-seven (33.3%) patients reported a decisional conflict. These patients had lower MS knowledge and more illness uncertainty, anxiety, depressive symptoms, fatigue, subjective symptom severity, a threatening illness perception, and poorer quality of life than their counterparts. Lack of decisional conflict was associated with MS knowledge (Odds ratio [OR]=1.195, 95% CI 1.045, 1.383, p=0.013), self-management (OR=1.049, 95% CI 1.013, 1.093, p=0.018), and regret after a healthcare decision (OR=0.860, 95% CI 0.756, 0.973, p=0.018) in the multivariate analysis. Conclusion: Decisional conflict regarding the selection of a disease-modifying therapy was a common phenomenon in patients with mid-stage RRMS. Identifying f -Abstract Truncated-
medicine, general & internal